Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate for infarct size reduction after acute STEMI
MOH_2026-10-15_017090Phase 2Not yet recruiting
- Sponsor
- ד"ר רועי קופמן
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glatiramer acetate in myocardial infarction (MI) (2 arms), sponsored by ד"ר רועי קופמן. Primary endpoint: Myocardial infarct size. Planned start May 2026; status: not yet recruiting.
02
Drugs
glatiramer acetate
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2026-10-15_017090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-15_017090.